Information Provided By:
Fly News Breaks for September 17, 2015
MRTX
Sep 17, 2015 | 06:58 EDT
Piper Jaffray analyst Charles Duncan downgraded Mirati Therapeutics to Neutral citing the rally in shares since the "impressive" World Lung data. Duncan cut his price target for the stock to $45 from $50 to reflect dilution from yesterday's secondary offering.
News For MRTX From the Last 2 Days
There are no results for your query MRTX